Pyro-Glu Abeta

A major component of neuritic plaques in Alzheimer's disease

References SySy pyro-Glu Abeta antibodies

Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth HU, Blennow K, Wirths O & Bayer TA (2012) Pyroglutamate A(beta) aggravates behavioral deficits in 5XFAD mice. Journal of Biological Chemistry Jan 20. [Epub ahead of print] Clone 2-48; IHC, Clone 1-57; IP

Venkataramani V, Wirths O, Budka H, Härtig W, Kovacs GG & Bayer TA (2012). Antibody 9D5 Recognizes Oligomeric Pyroglutamate Amyloid-β in a Fraction of Amyloid-β Deposits in Alzheimer's Disease without Cross-Reactivity with other Protein Aggregates. Journal of Alzheimer's Disease Jan 9. [Epub ahead of print] Clone 9D5; IHC

Bayer TA & Wirths O (2011). Intraneuronal Aβ as a trigger for neuron loss: can this be translated into human pathology? Biochemical Societa Transactions 39: 857-61. Clone 9D5

Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawhar S, Kumar S, Multhaup G, Walter J, Ingelsson M, Degerman-Gunnarsson M, Kalimo H, Huitinga I, Lannfelt L & Bayer TA (2010). Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. Journal of Biological Chemistry 285: 41517-24. Clone 9D5; WB, IHC, ELISA

Alexandru A, Jagla W, Graubner S, Becker A, Bäuscher C, Kohlmann S, Sedlmeier R, Raber KA, Cynis H, Rönicke R, Reymann KG, Petrasch-Parwez E, Hartlage-Rübsamen M, Waniek A, Rossner S, Schilling S, Osmand AP, Demuth HU & von Hörsten S (2011). Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation. Journal of Neuroscience 31: 12790-801 rabbit antibody; IHC

Hartlage-Rübsamen M, Morawski M, Waniek A, Jäger C, Zeitschel U, Koch B, Cynis H, Schilling S, Schliebs R, Demuth HU & Roßner S (2011). Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms. Acta Neuropathologica 121: 705-19. Clone 2-48 and rabbit antibody; IHC

Jawhar S, Trawicka A, Jenneckens C, Bayer TA & Wirths O (2010). Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiology of Aging 33(1): 196.e29-40. Clone 2-48; IHC

Härtig W, Goldhammer S, Bauer U, Wegner F, Wirths O, Bayer TA & Grosche J (2010). Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice. Journal of Chemical Neuroanatomy 40: 82-92 Clone 2-48; IHC

Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, Lannfelt L & Bayer TA (2010). Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. Journal of Neural Transmission 117: 85-96. Clone 2-48; WB, IHC

Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU & Bayer TA (2009). Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathologica 118: 487-96. Clone 2-48; WB in supplement

General references pyro-Glu Abeta

Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU & Rossner S (2008). Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nature Medicine 14: 1106-11.

Hook V, Schechter I, Demuth HU & Hook G (2008). Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease. Biological Chemistry 389: 993-1006. Review

Böhme L, Hoffmann T, Manhart S, Wolf R & Demuth HU (2008). Isoaspartate-containing amyloid precursor protein-derived peptides alter efficacy and specificity of potential beta-secretases. Biological Chemistry 389: 1055-66.

Schilling S, Appl T, Hoffmann T, Cynis H, Schulz K, Jagla W, Friedrich D, Wermann M, Buchholz M, Heiser U, von Hörsten S & Demuth HU (2008). Inhibition of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ. Journal of Neurochemistry 106: 1225-36.

Holtzman DM (2002). Abeta conformational change is central to Alzheimer's disease. Neurobiology of Aging 23: 1085-8. no abstract available

Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H, Beyermann M, Schleuder D, Jahn H, Rüther E, Kornhuber J, Annaert W, De Strooper B & Saftig P (2001). Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. Journal of Biological Chemistry 276: 42645-57.

Wood SJ, Maleeff B, Hart T & Wetzel R (1996). Physical, morphological and functional differences between ph 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Abeta. Journal of Molecular Biology 256: 870-7.

Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ & Roher AE (1996). Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. Journal of Biological Chemistry 271: 4077-81.